Tango Therapeutics, Inc. (TNGX) - Stock Analysis
Last updated: Mar 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative biotech momentum setup: shares have broken out ~31% over 21 days (12.5â16.45) above prior consolidation, supported by fresh analyst coverage (Moderate Buy), new institutional buying and upcoming JPMorgan presentation. With resistance near ~17 and strong recent ROC, any positive clinical or corporate update could fuel a further momentum spike in the short term, though cash burn and lack of near-term data keep risk high.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High liquidity ⢠Persistent losses ⢠Financing reliance TNGX combines a very strong liquidity/low-leverage balance sheet with persistent operating losses, high R&D-driven cash burn, low asset efficiency, and dependence on external financing that makes its current market valuation look rich relative to book.
Price Behavior
Key Price Behavior Insights: ⢠Strong momentum ⢠Overbought RSI ⢠Gap-driven rally Support Level: $11.14â$12.90 Resistance Level: $17.30 Bullish short-term trend with price at $17.30 well above the last month moving average (~$13.70), but an RSI ~75 and the large gap from ~$12.35â$16.83 raise overbought/pullback risk toward $11.14â$12.90 if $17.30 fails.
Sentiment & News
Key News Insights: ⢠Erasca collaboration ⢠Institutional buying ⢠Analyst downgrade Tango's shares surged after an Erasca collaboration and fresh institutional buying as management pivots vopimetostat toward lateâstage development, balanced by an analyst downgrade and insider selling.
AI Summary
Tango has shifted from an earlyâstage R&D spec to a catalystâdriven clinical developer with a multiâyear cash cushion and partnership funding that materially reduces immediate dilution risk, making the stock a tactical trade centered on imminent vopimetostat and combo readouts. The key action point: size positions around nearâterm clinical and partner milestones because a negative pivotal/combination outcome or faster burn without nonâdilutive funding would sharply compress value.
Description
Tango Therapeutics is a Cambridge, Massachusettsâbased biotechnology company that discovers and develops small-molecule therapies for cancer. Its lead candidate, TNG908, is a PRMT5 inhibitor targeting tumors with MTAP deletions, and the pipeline includes inhibitors directed at USP1 for BRCA1/2-mutant cancers and a program for STK11-mutant tumors. The company maintains a strategic discovery and development collaboration with Gilead Sciences and was founded in 2017.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | TNGX | Tango Therapeutics, Inc. | Speculative biotech momentum setup: shares have broken out ~31% over 21 days (12.5â16.45) above prior consolidation, supported by fresh analyst coverage (Moderate Buy), new institutional buying and upcoming JPMorgan presentation. With resistance near ~17 and strong recent ROC, any positive clinical or corporate update could fuel a further momentum spike in the short term, though cash burn and lack of near-term data keep risk high. | Active | +4.9% |